

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6693481

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST
SEQUENCE:	1

CONVEYING PARTY DATA

Name	Execution Date
BANK OF AMERICA, N.A.	05/05/2021

RECEIVING PARTY DATA

Name:	JAZZ PHARMACEUTICALS, INC.
Street Address:	3180 PORTER DRIVE
City:	PALO ALTO
State/Country:	CALIFORNIA
Postal Code:	94304
Name:	JAZZ PHARMACEUTICALS IRELAND LIMITED
Street Address:	ONE BURLINGTON ROAD, CONNAUGHT HOUSE, FOURTH FLOOR
City:	DUBLIN 4
State/Country:	IRELAND
Name:	JAZZ PHARMACEUTICALS INTERNATIONAL LIMITED
Street Address:	CLARENDON HOUSE, 2 CHURCH STREET
City:	HAMILTON HM 11
State/Country:	BERMUDA
Name:	JAZZ PHARMACEUTICALS INTERNATIONAL III LIMITED
Street Address:	CLARENDON HOUSE, 2 CHURCH STREET
City:	HAMILTON HM 11
State/Country:	BERMUDA
Name:	CELATOR PHARMACEUTICALS, INC.
Street Address:	200 PRINCETON SOUTH CORPORATE CENTER, SUITE 180
City:	EWING
State/Country:	NEW JERSEY
Postal Code:	08628
Name:	CAVION, INC.
Street Address:	3170 PORTER DRIVE
City:	PALO ALTO
State/Country:	CALIFORNIA
Postal Code:	94304

PATENT

PROPERTY NUMBERS Total: 94

Property Type	Number
Patent Number:	5795864
Patent Number:	5891849
Patent Number:	6054429
Patent Number:	5364842
Patent Number:	6599905
Patent Number:	6780889
Patent Number:	6803464
Patent Number:	7262219
Patent Number:	7268109
Patent Number:	7524812
Patent Number:	7668730
Patent Number:	7765106
Patent Number:	7765107
Patent Number:	7797171
Patent Number:	7851506
Patent Number:	7895059
Patent Number:	8263650
Patent Number:	8324275
Patent Number:	8461203
Patent Number:	8513198
Patent Number:	8589182
Patent Number:	8591922
Patent Number:	8609651
Patent Number:	8653033
Patent Number:	8716279
Patent Number:	8731963
Patent Number:	8765680
Patent Number:	8771735
Patent Number:	8772306
Patent Number:	8778398
Patent Number:	8859619
Patent Number:	8901173
Patent Number:	8952029
Patent Number:	7833973
Patent Number:	7956030
Patent Number:	7977307
Patent Number:	8268774

Property Type	Number
Patent Number:	8457988
Patent Number:	8952062
Patent Number:	9050302
Application Number:	13071369
Application Number:	14045673
Application Number:	13837714
Application Number:	14205423
Application Number:	14228192
Application Number:	14328795
Application Number:	14334694
Application Number:	14196603
Application Number:	14219904
Application Number:	14219941
Application Number:	14250116
Application Number:	14256860
Application Number:	14295098
Application Number:	14310533
Application Number:	14475320
Application Number:	62061489
Application Number:	62117889
Application Number:	14707914
Application Number:	15047586
Application Number:	15057898
Patent Number:	7238367
Patent Number:	7744921
Patent Number:	7842676
Patent Number:	7850090
Patent Number:	8022279
Patent Number:	8092828
Patent Number:	8431806
Patent Number:	8486924
Patent Number:	8518437
Patent Number:	9271931
Application Number:	13122454
Application Number:	13905015
Application Number:	13969449
Application Number:	14352662
Application Number:	14931679

Property Type	Number
Application Number:	14990167
Application Number:	62192973
Application Number:	62252396
Application Number:	62254109
Application Number:	15385447
Application Number:	14788524
Application Number:	15651655
Application Number:	15695913
Application Number:	62656486
Application Number:	62657161
Application Number:	62658918
Application Number:	15870355
Application Number:	15769980
Application Number:	16486399
Application Number:	13581390
Application Number:	16608355
Application Number:	16608401
Application Number:	13609942
Application Number:	16685276

CORRESPONDENCE DATA

Fax Number: (800)914-4240

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 800-713-0755

Email: Michael.Violet@wolterskluwer.com, ECarrera@cahill.com

Correspondent Name: CT CORPORATION

Address Line 1: 4400 EASTON COMMONS WAY

Address Line 2: SUITE 125

Address Line 4: COLUMBUS, OHIO 43219

NAME OF SUBMITTER: ELAINE CARRERA

SIGNATURE: /Elaine Carrera/

DATE SIGNED: 05/05/2021

Total Attachments: 12

source=a067. Project Geneva - U.S. Patent Release#page1.tif

source=a067. Project Geneva - U.S. Patent Release#page2.tif

source=a067. Project Geneva - U.S. Patent Release#page3.tif

source=a067. Project Geneva - U.S. Patent Release#page4.tif

source=a067. Project Geneva - U.S. Patent Release#page5.tif

source=a067. Project Geneva - U.S. Patent Release#page6.tif

source=a067. Project Geneva - U.S. Patent Release#page7.tif
source=a067. Project Geneva - U.S. Patent Release#page8.tif
source=a067. Project Geneva - U.S. Patent Release#page9.tif
source=a067. Project Geneva - U.S. Patent Release#page10.tif
source=a067. Project Geneva - U.S. Patent Release#page11.tif
source=a067. Project Geneva - U.S. Patent Release#page12.tif

RELEASE OF SECURITY INTEREST IN PATENTS

This RELEASE OF SECURITY INTEREST IN PATENTS (this “Release”), dated as of May 5, 2021 (the “Effective Date”), is made by Bank of America, N.A., in its capacity as Collateral Agent (the “Agent”), in favor of the grantor parties identified on the signature page hereto (the “Grantors”).

WHEREAS, pursuant to that certain Security Agreement, dated as of June 18, 2015, by and among the Agent, the Grantors and certain other parties thereto (as amended, amended and restated, supplemented or otherwise modified from time to time, the “Security Agreement”), the Grantors granted to the Agent, in its capacity as Collateral Agent, a security interest in and to certain collateral;

WHEREAS, pursuant to the Security Agreement, certain Grantors executed and delivered (a) a Patent Security Agreement, dated as of June 18, 2015 the “2015 Patent Security Agreement”), (b) Supplement No. 1 to Patent Security Agreement, dated as of June 27, 2016 (“Supplement No. 1”), (c) a Patent Security Agreement, dated as of July 12, 2016 (the “2016 Patent Security Agreement”), (d) Supplement No. 3 to Patent Security Agreement, dated as of June 7, 2018 (“Supplement No. 3”) and (e) Supplement No. 4 to Patent Security Agreement, dated as of December 6, 2019 (“Supplement No. 4” and together with the 2015 Patent Security Agreement, Supplement No. 1, the 2016 Patent Security Agreement and Supplement No. 3, the “Patent Security Agreements”) for recordal with the United States Patent and Trademark Office;

WHEREAS, (a) the 2015 Patent Security Agreement was recorded with the United States Patent and Trademark Office on June 19, 2015 at Reel/Frame 035936/0200, (b) Supplement No. 1 was recorded with the United States Patent and Trademark Office on July 5, 2016 at Reel/Frame 039254/0453, (c) the 2016 Patent Security Agreement was recorded with the United States Patent and Trademark Office on July 12, 2016 at Reel/Frame 039312/0397, (d) Supplement No. 3 was recorded with the United States Patent and Trademark Office on February 1, 2019 at Reel/Frame 048208/0585 and (e) Supplement No. 4 was recorded with the United States Patent and Trademark Office on December 9, 2019 at Reel/051225/0686;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby agrees as follows:

1. Defined Terms. All capitalized terms used, but not otherwise defined herein, shall have the respective meanings ascribed in or otherwise referenced in the Security Agreement or the Patent Security Agreements, as applicable.

2. Release. The Agent, without representation or warranty of any kind, hereby releases, discharges, terminates and cancels all of its security interest in and to all Patents and patent applications set forth Schedule I attached hereto, (the “Patent Collateral”), arising under the Security Agreement and the Patent Security Agreements. If and to the extent that the Agent has acquired any right, title or interest in and to the Patent Collateral under the Patent Security Agreements, the Agent, without representation or warranty of any kind, hereby re-transfers, re-conveys and re-assigns such right, title or interest to the Grantors.

3. Termination. The Agent, without representation or warranty of any kind, terminates and cancels the Patent Security Agreements.

4. Further Assurances. The Agent agrees to take all further actions, and provide to the Grantors and their successors, assigns or other legal representatives, all such cooperation and assistance (including,

without limitation, the execution and delivery of any and all documents or other instruments), reasonably requested by the Grantors, at the Grantors' sole cost and expense, to more fully and effectively effectuate the purposes of this Release.

5. Governing Law. This Release shall be governed exclusively under the laws of the State of New York, without regard to conflicts of law or choice of law principles.

IN WITNESS WHEREOF, the Agent has caused this Release to be executed by its duly authorized representative as of the Effective Date:

**BANK OF AMERICA, N.A., acting in its
capacity as Agent**

By: 

Name: Henry C. Pennell

Title: Vice President

GRANTORS:

JAZZ PHARMACEUTICALS, INC.

**JAZZ PHARMACEUTICALS IRELAND
LIMITED**

**JAZZ PHARMACEUTICALS
INTERNATIONAL LIMITED**

**JAZZ PHARMACEUTICALS
INTERNATIONAL III LIMITED**

CELATOR PHARMACEUTICALS, INC.

CAVION, INC.

SCHEDULE I**Reel/Frame 035936/0200****Patents:**

	Assignee	Patent Title	Serial No. Filing Date	Patent No. Issue Date
1.	Jazz Pharmaceuticals International Limited	Stable omega conopeptide formulations	08496847 06/27/1995	5795864 08/18/1998
2.	Jazz Pharmaceuticals International Limited	Methods and formulations for preventing progression of neuropathic pain	08965918 11/07/1997	5891849 04/06/1999
3.	Jazz Pharmaceuticals International Limited	Improved epidural method of producing analgesia	08613400 03/08/1996	6054429 04/25/2000
4.	Jazz Pharmaceuticals International Limited	Method of producing analgesia	08081863 6/23/1993	5364842 11/15/1994
5.	Jazz Pharmaceuticals, Inc.	Pyrazine compounds	09855703 05/16/2001	6599905 07/29/2003
6.	Jazz Pharmaceuticals, Inc.	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	10194021 07/11/2002	6780889 08/24/2004
7.	Jazz Pharmaceuticals, Inc.	Process for the preparation of pyrazine compounds	10275457 11/05/2002	6803464 10/12/2004
8.	Jazz Pharmaceuticals, Inc.	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	10841709 05/07/2004	7262219 08/28/2007
9.	Jazz Pharmaceuticals International Limited	Method for reducing pain	10956252 10/01/2004	7268109 09/11/2007
10.	Jazz Pharmaceuticals International Limited	Pharmaceutical formulation comprising ziconotide	11831696 07/31/2007	7524812 04/28/2009
11.	Jazz Pharmaceuticals, Inc.	SENSITIVE DRUG DISTRIBUTION SYSTEM AND METHOD	10322348 12/17/2002	7668730 02/23/2010
12.	Jazz Pharmaceuticals, Inc.	Sensitive drug distribution system and method	10979665 11/02/2004	7765106 07/27/2010
13.	Jazz Pharmaceuticals, Inc.	Sensitive drug distribution system and method	11097985 04/01/2005	7765107 07/27/2010
14.	Jazz Pharmaceuticals, Inc.	Sensitive drug distribution system and method	11097651 04/01/2005	7797171 09/14/2010

	Assignee	Patent Title	Serial No. Filing Date	Patent No. Issue Date
15.	Jazz Pharmaceuticals, Inc.	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	11777877 07/13/2007	7851506 12/14/2010
16.	Jazz Pharmaceuticals, Inc.	Sensitive drug distribution system and method	12704097 02/11/2010	7895059 02/22/2011
17.	Jazz Pharmaceuticals, Inc.	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	13446940 04/13/2012	8263650 09/11/2012
18.	Jazz Pharmaceuticals, Inc.	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	13446892 04/13/2012	8324275 12/04/2012
19.	Jazz Pharmaceuticals, Inc.	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	13182324 07/13/2011	8461203 06/11/2013
20.	Jazz Pharmaceuticals International Limited	Pharmaceutical formulation for reducing pain	13616607 09/14/2012	8513198 08/20/2013
21.	Jazz Pharmaceuticals, Inc.	Sensitive drug distribution system and method	13595676 08/27/2012	8589182 11/19/2013
22.	Jazz Pharmaceuticals Ireland Limited	Gamma-hydroxybutyrate compositions and their use for the treatment of disorders	13739886 01/11/2013	8591922 11/26/2013
23.	Jazz Pharmaceuticals, Inc.	Pharmaceutical compositions of benzodiazepines and method of use thereof	11897028 08/27/2007	8609651 12/17/2013
24.	Jazz Pharmaceuticals International Limited	Method for administering omega-conopeptide	13791715 03/08/2013	8653033 02/18/2014
25.	Jazz Pharmaceuticals, Inc.	Pharmaceutical compositions of clonazepam and method of use thereof	11897002 08/27/2007	8716279 05/06/2014
26.	Jazz Pharmaceuticals, Inc.	Sensitive drug distribution system and method	13592202 08/22/2012	8731963 05/20/2014
27.	Jazz Pharmaceuticals International Limited	Method for administering omega-conopeptide	14133303 12/18/2013	8765680 07/01/2014
28.	Jazz Pharmaceuticals, Inc.	Immediate release dosage forms of sodium oxybate	12264709 11/04/2008	8771735 07/08/2014
29.	Jazz Pharmaceuticals Ireland Limited	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	13872997 04/29/2013	8772306 07/08/2014
30.	Jazz Pharmaceuticals, Inc.	Immediate release formulations and dosage forms of gamma-hydroxybutyrate	12773599	8778398 07/15/2014

	Assignee	Patent Title	Serial No. Filing Date	Patent No. Issue Date
			05/04/2010	
31.	Jazz Pharmaceuticals, Inc.	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	13685561 11/26/2012	8859619 10/14/2014
32.	Jazz Pharmaceuticals Ireland Limited	Gamma-hydroxybutyrate compositions and their use for the treatment of disorders	14172751 02/04/2014	8901173 12/02/2014
33.	Jazz Pharmaceuticals Ireland Limited	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	13873000 04/29/2013	8952029 02/10/2015
34.	Jazz Pharmaceuticals International Limited	Pharmaceutical formulations for reducing pain	12/483673 06/12/2009	7833973 10/27/2010
35.	Jazz Pharmaceuticals International Limited	Method for reducing pain with ziconotide and baclofen	12/898525 10/05/2010	7956030 05/18/2011
36.	Jazz Pharmaceuticals International Limited	Method for reducing pain with ziconotide and morphine	12/898516 10/05/2010	7977307 06/22/2011
37.	Jazz Pharmaceuticals International Limited	Method for reducing pain	13/176568 07/05/2011	8268774 08/29/2012
38.	Jazz Pharmaceuticals, Inc.	Sensitive drug distribution system and method	13/595757 08/27/2012	8457988 05/15/2013
39.	Jazz Pharmaceuticals, Inc.	Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy	13/787437 03/06/2013	8952062 01/21/2015
40.	Jazz Pharmaceuticals Ireland Limited	METHOD OF ADMINISTRATION OF GAMMA HYDROXYBUTYRATE WITH MONOCARBOXYLATE TRANSPORTERS	13/837714 03/15/2013	9050302 05/20/2015

Patent Applications:

	Assignee	Patent Title	Serial No. Filing Date
1.	Jazz Pharmaceuticals, Inc.	Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances	13071369 03/24/2011
2.	Jazz Pharmaceuticals Ireland Limited	Gamma-hydroxybutyrate compositions and their use for the treatment of disorders	14045673 10/03/2013
3.	Jazz Pharmaceuticals Ireland Limited	Method of administration of gamma hydroxybutyrate with monocarboxylate transporters	13837714 03/15/2013

	Assignee	Patent Title	Serial No. Filing Date
4.	Jazz Pharmaceuticals International III Limited and SK Biopharmaceuticals Co., Ltd.	Treatment of Cataplexy	14205423 03/12/201 4
5.	Jazz Pharmaceuticals, Inc.	Methods of administering drugs in an implantable multi-chamber pump	14228192 03/27/201 4
6.	Jazz Pharmaceuticals International III Limited and SK Biopharmaceuticals Co., Ltd.	Promotion of Smoking Cessation	14328795 07/11/201 4
7.	Jazz Pharmaceuticals International III Limited and SK Biopharmaceuticals Co., Ltd.	Treatment for Obesity	14334694 07/18/201 4
8.	Jazz Pharmaceuticals, Inc.	SENSITIVE DRUG DISTRIBUTION SYSTEM AND METHOD	14196603
9.	Jazz Pharmaceuticals, Inc.	SENSITIVE DRUG DISTRIBUTION SYSTEM AND METHOD	14219904
10.	Jazz Pharmaceuticals, Inc.	SENSITIVE DRUG DISTRIBUTION SYSTEM AND METHOD	14219941
11.	Jazz Pharmaceuticals, Inc.	MICROBIOLOGICALLY SOUND AND STABLE SOLUTIONS OF GAMMA- HYDROXYBUTYRATE SALT FOR THE TREATMENT OF NARCOLEPSY	14250116
12.	Jazz Pharmaceuticals, Inc.	SYSTEMS, METHODS AND COMPUTER-READABLE MEDIA FOR LIMITED DISTRIBUTION OF SPECIALTY DRUG USING A COMPUTER HUB OPERATING AT A SINGLE ACCESS POINT	14256860
13.	Jazz Pharmaceuticals, Inc.	IMMEDIATE RELEASE FORMULATIONS AND DOSAGE FORMS OF GAMMA-HYDROXYBUTYRATE	14295098
14.	Jazz Pharmaceuticals International Limited	METHOD FOR ADMINISTERING OMEGA-CONOPEPTIDE	14310533
15.	Jazz Pharmaceuticals, Inc.	DEVICES AND METHODS FOR FACILITATING AND CONTROLLING USE OF A MEDICATION	14475320
16.	Jazz Pharmaceuticals, Inc.	Methods of Treating Viral Diseases with Defibrotide	62061489
17.	Jazz Pharmaceuticals, Inc.	GHB Formulation And Method For Its Manufacture	62117889

Reel/Frame 039254/0453**Patents:**

	Assignee	Patent Title	Serial No. Filing Date	Patent No. Issue Date	Note
1.	Jazz Pharmaceuticals Ireland Limited	METHOD OF ADMINISTRATION OF GAMMA HYDROXYBUTYRATE WITH MONOCARBOXYLATE TRANSPORTERS	14707914 05/08/2015	Published as 20160015662 01/21/2016	

Patent Applications:

	Assignee	Patent Title	Serial No. Filing Date
2.	Jazz Pharmaceuticals Ireland Limited	GHB Formulation and Method for Its Manufacture	15/047,586
3.	Jazz Pharmacueticals, Inc.	Sensitive Drug Distribution System and Method	15,057/898

Reel/Frame 039312/0397**Registrations:**

	Assignee	Patent Title	Serial No. Filing Date	Patent No. Issue Date
1.	Celator Pharmaceuticals, Inc.	Liposome loading with metal ions	10264818 10/03/2002	7238367 07/03/2007
2.	Celator Pharmaceuticals, Inc.	Liposome loading with metal ions	11842130 08/20/2007	7744921 06/29/2010
3.	Celator Pharmaceuticals, Inc.	Fixed ratio drug combination treatments for solid tumors	11586215 10/25/2006	7842676 11/30/2010
4.	Celator Pharmaceuticals, Inc.	Spikeless tie plate fasteners, pre-plated railroad ties and related assemblies and methods	12004891 12/21/2007	7850090 12/14/2010
5.	Celator Pharmaceuticals, Inc.	Liposomal formulations of anthracycline agents and cytidine analogs	11587112 08/02/2007	8022279 09/20/2011
6.	Celator Pharmaceuticals, Inc.	Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders	12032583 02/15/2008	8092828 01/10/2012
7.	Celator Pharmaceuticals, Inc.	Liposomal formulations of anthracycline agents and cytidine analogs	13237807 09/20/2011	8431806 04/30/2013
8.	Celator Pharmaceuticals, Inc.	Taxane delivery system	12741954 09/13/2010	8486924 07/16/2013
9.	Celator Pharmaceuticals, Inc.	Lipid carrier compositions with enhanced blood stability	10294474 11/13/2002	8518437 08/27/2013
10.	Celator Pharmaceuticals, Inc.	Compositions for Delivery of Drug Combinations	10553373 03/22/2007	9271931 03/01/2016

Applications:

	Assignee	Patent Title	Serial No. Filing Date	Patent No. Issue Date
1.	Celator Pharmaceuticals, Inc.	Combination methods and compositions	13122454 05/10/2011	20110223241 09/15/2011
2.	Celator Pharmaceuticals, Inc. and The Trustees of Princeton University	Particulate constructs for release of active agents	13905015 05/29/2013	20130336915 12/19/2013
3.	Celator Pharmaceuticals, Inc. and The Trustees of Princeton University	Particulate constructs for release of active agents	13969449 08/16/2013	20130337078 12/19/2013
4.	Celator Pharmaceuticals, Inc.	Method of lyophilizing liposomes	14352662 04/17/2014	20140255475 09/11/2014
5.	Celator Pharmaceuticals, Inc.	Platinum drug formulations	14931679 11/03/2015	20160058704 03/03/2016
6.	Celator Pharmaceuticals, Inc.	Compositions for delivery of drug combinations	14990167 01/07/2016	20160113871 04/28/2016
7.	Celator Pharmaceuticals, Inc.	Improved combinations of Taxanes and molecularly targeted potentiating agents	62192,973	
8.	Celator Pharmaceuticals, Inc.	Improved combinations of protein kinase inhibitors	62252,396	
9.	Celator Pharmaceuticals, Inc. Oregon Health and Science University	Assays and methods for selecting a treatment regimen for a subject with Leukemia	62254,109	

Reel/Frame 048208/0585**Patents:**U.S. Patents and Applications:

	Owner	Patent Title	Appl. No. Filing Date	Patent No. Issue Date
1.	Jazz Pharmaceuticals Ireland Limited	Gamma-Hydroxybutyrate Compositions And Their Uses For The Treatment Of Disorders	15385447 12/20/2016	
2.	Jazz Pharmaceuticals International Limited	Method for Administering Omega- Conopeptide	14788524 06/30/2015	9707270 07/18/2017
3.	Jazz Pharmaceuticals International Limited	Method for Administering Omega- Conopeptide	15651655 07/17/2017	
4.	Jazz Pharmaceuticals International III Limited	Formulations Of (R)-2-Amino-3- Phenylpropyl Carbamate	15695913 09/05/2017	
5.	Jazz Pharmaceuticals, Inc.	Defibrotide for the prevention and treatment of cytokine release syndrome	62/656486	
6.	Jazz Pharmaceuticals, Inc.	Defibrotide for the prevention and treatment of cytokine release syndrome	62/657161	
7.	Jazz Pharmaceuticals, Inc.	Systems, methods, and apparatus for diagnosing narcolepsy using neural networks	62/658918	

Reel/Frame 051225/0686

Patents:

U.S. Patents and Applications:

	Owner	Patent Title	Appl. No. Filing Date	Patent No.
1.	Cavion, Inc.	INTERLACED METHOD OF TREATING CANCER OR A PRECANCEROUS CONDITION	15/870,355	
2.	Cavion, Inc.	METHODS FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS	15/769,980	
3.	Cavion, Inc.	CALCIUM CHANNEL INHIBITORS	16/486,399	
4.	Cavion, Inc.	CANCER DIAGNOSIS AND IMAGING	13/581,390	9,427,429
5.	Cavion, Inc.	METHODS FOR TREATING DRAVET SYNDROME	16/608,355	
6.	Cavion, Inc.	METHODS FOR IMPROVING MEMORY AND COGNITION AND FOR TREATING MEMORY AND COGNITIVE DISORDERS	16/608,401	
7.	Cavion, Inc.	ANTAGONISTS OF PRODUCTS OF THE HS.459642 UNIGENE CLUSTER FOR THE INHIBITION OF PROLIFERATION, DEVELOPMENT OR DIFFERENTIATION OF STEM CELLS INCLUDING CANCER STEM CELLS	13/609,942	
8.	Cavion, Inc.	ANTAGONISTS OF PRODUCTS OF THE HS.459642 UNIGENE CLUSTER FOR THE INHIBITION OF PROLIFERATION, DEVELOPMENT OR DIFFERENTIATION OF STEM CELLS INCLUDING CANCER STEM CELLS	16/685,276	